Background Intratumoral heterogeneity (ITH) and subclonal antigen expression blunt antitumor immunity and are associated with poor responses to immune-checkpoint blockade immunotherapy (ICB) in patients with cancer. The underlying mechanisms however thus far remained elusive. preventing the design of novel treatment approaches for patients with high ITH tumors. Methods We developed a ... https://www.diegojavierfares.com/limited-value-Winnipeg-Parks-Shrub-Rose-big-savings/